Note also that the compounding market tightened in 2025 to 2026 after the FDA removed semaglutide and tirzepatide from shortage, so pharmacy access to compounded products now generally requires a documented clinical rationale
The Muscle-Building Peptide That Doesn't Exist Notice what's missing from the list above
Do the same for the top of the vial of your vitamin B12 solution
Under review simply means the FDA is still assessing: Safety Clinical relevance Regulatory appropriateness It does not mean: The peptide is approved The peptide is widely available The peptide is appropriate for general use At this stage, access to many of these substances may remain limited, inconsistent, or restricted, and quality can vary outside regulated pathways
Christine Collins, MD ensures your body is receiving the precise vitamins and minerals it needs to thrive
(2021) Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke